{
  "paper_id": "549a77a27e6c3cf72075693d5382f8ed14bc4c15",
  "metadata": {
    "title": "********** Le taux de mortalité du SRAS a été estimé à 13,2 % chez les moins de 60 ans et à 43,3 % chez les plus de 60 ans Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in",
    "coda_data_split": "train",
    "coda_paper_id": 8477,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. 4 W underink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group : Continuation of a randomized, double-blind, multicenter study linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003 ; 25 : 980-92. 5 Fung HB, Kirschenbaum HL, Ojofeitimi BO : Linezolid: an oxazolidinone antimicrobiol agent. Clin Ther 2001 ; 23 : 356-91. 6",
      "sentences": [
        [
          {
            "segment_text": "publicly funded repositories , such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "4 W underink RG , Cammarata SK ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "Oliphant TH , Kollef MH ; Linezolid Nosocomial Pneumonia Study Group : Continuation of a randomized ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "double-blind , multicenter study linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Clin Ther 2003 ; 25 : 980-92 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "5 Fung HB , Kirschenbaum HL ,",
            "crowd_label": "other"
          },
          {
            "segment_text": "Ojofeitimi BO : Linezolid : an oxazolidinone antimicrobiol agent .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Clin Ther 2001 ; 23 : 356-91 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "6",
            "crowd_label": "other"
          }
        ]
      ]
    },
    {
      "original_text": "P erry CM, Jarvis B : Linezolid: a review of its use in the management of serious gram positive infections.",
      "sentences": [
        [
          {
            "segment_text": "P erry CM , Jarvis B : Linezolid : a review of its use in the management of serious gram positive infections .",
            "crowd_label": "other"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "2",
    "sentence_num": "8",
    "segment_num": "11",
    "token_num": "149"
  }
}